학술논문
Monitoring Temporal Changes in SARS-CoV-2 Spike Antibody Levels and Variant-Specific Risk for Infection, Dominican Republic, March 2021–August 2022
Document Type
article
Author
Eric J. Nilles; Michael de St. Aubin; Devan Dumas; William Duke; Marie Caroline Etienne; Gabriela Abdalla; Petr Jarolim; Timothy Oasan; Salome Garnier; Naomi Iihoshi; Beatriz Lopez; Lucia de la Cruz; Yosanly Cornelio Puello; Margaret Baldwin; Kathryn W. Roberts; Farah Peña; Kara Durski; Isaac Miguel Sanchez; Sarah M. Gunter; Alexander R. Kneubehl; Kristy O. Murray; Allison Lino; Sarah Strobel; Amado Alejandro Baez; Colleen L. Lau; Adam Kucharski; Emily Zielinski Gutiérrez; Ronald Skewes-Ramm; Marietta Vasquez; Cecilia Then Paulino
Source
Emerging Infectious Diseases, Vol 29, Iss 4, Pp 723-733 (2023)
Subject
Language
English
ISSN
1080-6040
1080-6059
1080-6059
Abstract
To assess changes in SARS-CoV-2 spike binding antibody prevalence in the Dominican Republic and implications for immunologic protection against variants of concern, we prospectively enrolled 2,300 patients with undifferentiated febrile illnesses in a study during March 2021–August 2022. We tested serum samples for spike antibodies and tested nasopharyngeal samples for acute SARS-CoV-2 infection using a reverse transcription PCR nucleic acid amplification test. Geometric mean spike antibody titers increased from 6.6 (95% CI 5.1–8.7) binding antibody units (BAU)/mL during March–June 2021 to 1,332 (95% CI 1,055–1,682) BAU/mL during May–August 2022. Multivariable binomial odds ratios for acute infection were 0.55 (95% CI 0.40–0.74), 0.38 (95% CI 0.27–0.55), and 0.27 (95% CI 0.18–0.40) for the second, third, and fourth versus the first anti-spike quartile; findings were similar by viral strain. Combining serologic and virologic screening might enable monitoring of discrete population immunologic markers and their implications for emergent variant transmission.